» Articles » PMID: 17542674

Thyroid Cancer in HCV-related Chronic Hepatitis Patients: a Case-control Study

Overview
Journal Thyroid
Date 2007 Jun 5
PMID 17542674
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The present study prospectively investigated prevalence and features of thyroid cancer in patients with hepatitis C virus-related chronic hepatitis (HCV+) in comparison to two samples from the general population with different iodine intake.

Design: We studied the prevalence of thyroid cancer in 308 unselected HCV+ patients in comparison to two population-based, gender- and age-matched control groups: 1) 616 subjects from an iodine deficient area; 2) 616 subjects from an iodine-sufficient area. Thyroid status was assessed by measurement of circulating thyroid hormones and autoantibodies, thyroid ultrasonography, and when indicated, fine-needle aspiration cytology.

Main Outcome: Circulating thyrotropin, anti-thyroglobulin, and anti-thyroperoxidase antibodies levels, and the prevalence of hypothyroidism were significantly higher in HCV+ patients (p < 0.001 for all). Six patients with papillary thyroid cancer were detected among HCV+ patients, whereas no case was observed in control 1 (p = 0.001), and only one case was observed in control 2 (p = 0.003). In HCV+ patients 83% with thyroid cancer had evidence of thyroid autoimmunity vs 31% of the other HCV+ patients (p = 0.02).

Conclusions: These data suggest a high prevalence of thyroid papillary cancer in HCV+ patients, overall in presence of thyroid autoimmunity; careful thyroid monitoring is indicated during the follow-up of these patients.

Citing Articles

Xenotropic and polytropic retrovirus receptor 1 (XPR1) promotes progression of papillary thyroid carcinoma via the BRAF-ERK1/2-P53 signaling pathway.

Su Y, Mei L, Wu Y, Li C, Jiang T, Zhao Y J Endocrinol Invest. 2024; 48(3):633-652.

PMID: 39487939 DOI: 10.1007/s40618-024-02481-5.


Extrahepatic Cancer Risk in Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antivirals.

Tani J, Masaki T, Oura K, Tadokoro T, Morishita A, Kobara H Microorganisms. 2024; 12(9).

PMID: 39338599 PMC: 11434491. DOI: 10.3390/microorganisms12091926.


The Potential Role of Virus Infection in the Progression of Thyroid Cancer.

Wu Y, Jiang T, Su Y, Mei L, Sun T, Li Y World J Oncol. 2024; 15(3):382-393.

PMID: 38751704 PMC: 11092407. DOI: 10.14740/wjon1830.


Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia.

Pimenov N, Kostyushev D, Komarova S, Fomicheva A, Urtikov A, Belaia O Pathogens. 2022; 11(12).

PMID: 36558817 PMC: 9781887. DOI: 10.3390/pathogens11121482.


GLUT1 and ASCT2 Protein Expression in Papillary Thyroid Carcinoma Patients and Relation to Hepatitis C Virus: A Propensity-Score Matched Analysis.

Ibrahiem A, Fawzy M, Abdulhakim J, Toraih E Int J Gen Med. 2022; 15:2929-2944.

PMID: 35308569 PMC: 8932928. DOI: 10.2147/IJGM.S354108.